A Chinese-made coronavirus vaccine could be ready for market as early as the end of this year, China's State-owned Assets Supervision and Administration Commission (SASAC) said in a social media post.
In trials, more than 2,000 people have received vaccines developed by the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products. A vaccine could be ready for the market as early as the end of this year or early 2021, according to the May 29 post on Chinese social media platform WeChat.
-
-
Who Is Rajiv Mehta? Lilavati Hospital Trustee To Speak At NDTV World Summit 2026 -
Ex-CIA Director To Decode 'War In Times Of AI' At NDTV World Summit -
From Call Centre To Billion-Dollar Disruptor: Nikhil Kamath At NDTV World Summit -
'Every 5 Years, You'll See A New India': Swami Sarvapriyananda Ahead Of NDTV World Summit -
AI Can Think, But Can It Be Conscious? Swami Sarvapriyananda Weighs In -
Alain Ebobisse, Africa50 CEO, To Attend NDTV World Summit 2026. All About Him -
Kriti Sanon At NDTV World Summit: A Look At Her Career And Business Ventures -
Ex-CIA Director To Decode 'War In Times Of AI' At NDTV World Summit -
Who Is Vikram Rai, CEO, South Asia GE Aerospace, Set To Attend The NDTV World Summit 2026 -
Rahul Kanwal: The World Is Changing. What Comes Next? | NDTV World Summit 2026
Vaccines from the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products had entered Phase II clinical trials. Both groups are affiliated with state-owned pharmaceutical group Sinopharm, whose management is overseen by SASAC.
The Beijing Institute of Biological Products' production line will have an annual manufacturing capacity of 100 million to
120 million doses, according to the article.
China has five coronavirus vaccines in human trials. Neither company could be reached for comment on Saturday evening.
Track Latest News Live on NDTV.com and get news updates from India and around the world
